Molecular Imaging: Page 456

Neoprobe posts Q2 loss on higher sales

By AuntMinnie.com staff writers

Neoprobe of Dublin, OH, announced a net loss for the second quarter, although the firm's revenues edged higher on increased sales of its gamma detection systems.

July 25, 2007

Cedara debuts I-Response

By AuntMinnie.com staff writers

Cedara Software has released its I-Response workstation, which is designed to evaluate, assess, and monitor the effect of cancer therapy over time using data from multiple modalities.

July 24, 2007

DraxImage files for European clearance

By AuntMinnie.com staff writers

Canadian radiopharmaceutical firm DraxImage has filed an application for its sestamibi kit with European regulatory authorities.

July 24, 2007

IBA to equip fourth U.S. proton therapy center

By AuntMinnie.com staff writers

Hampton University in Hampton, VA, has broken ground for the Hampton University Proton Therapy Institute (HUPTI).

July 24, 2007

Dilon lands Pittsburgh installation

By AuntMinnie.com staff writers

Ultrasound and breast imaging facility Weinstein Imaging Associates of Pittsburgh has installed scintimammography technology from Dilon Technologies of Newport News, VA.

July 24, 2007

SUV readings vary on different PET systems, study finds

By Wayne Forrest

Standardized uptake values (SUVs) are one of several factors used to help distinguish malignant and benign etiologies. Multiple factors are known to cause variations in SUV, including uptake period, body weight, and reconstruction method. But researchers at the University of Maryland School of Medicine in Baltimore have found that SUVs can vary in PET systems manufactured by different vendors.

July 24, 2007

Draxis unveils management changes

Canadian radiopharmaceutical firm Draxis Health of Mississauga, Ontario, has announced several changes at the senior management level.

July 19, 2007

Draxis posts Q2 earnings estimate

By AuntMinnie.com staff writers

Canadian firm Draxis Health of Mississauga, Ontario, expects to post estimated diluted net earnings of 4¢ U.S. per share for the second quarter of 2007 (end-June 30).

July 19, 2007

PET findings prompt changes in therapy plans

By Brian Casey

July 18, 2007

Naviscan taps Mirabella as CEO

PET developer Naviscan PET Systems of San Diego announced that it has appointed Paul Mirabella as president and CEO.

July 18, 2007

PET changes oncology management, study shows

By Wayne Forrest

A multisite study in Australia has found that PET results can change treatment plans for cancer patients, as the modality provides more information on the extent, recurrence, and progression of the disease. The Australian PET Data Collection Project has collected data on whether the modality changed the management of patients with different types of cancer, such as ovarian cancer, metastatic melanoma, and colorectral cancer.

July 18, 2007

Duke MMIL designs novel SPECT/CT system for 3D breast imaging

July 17, 2007

Previous Page

Page 456 of 611

Next Page